JAMA Network
About The Study: In older patients with cancer and type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1RA) use was associated with lower all-cause mortality compared with dipeptidyl peptidase-4 inhibitor (DPP4i) use, with no significant difference relative to sodium-glucose cotransporter-2 inhibitor. The survival benefit over DPP4i persisted across age, sex, non-Hispanic white race, obesity status, and several cancer types (colorectal, lung, and breast).
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
